Sydney Dowell
Nurse Practitioner · Louisville, KYNPI 1144243379
Payments from drug & device makers
Across 318 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$576
- Amgen$440
- Novo Nordisk$277
- Boehringer Ingelheim$256
- Biohaven Pharmaceuticals, Inc.$229
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,447100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $1,302 |
| Pfizer | 43 | $576 |
| Amgen | 31 | $440 |
| Novo Nordisk | 10 | $277 |
| Boehringer Ingelheim | 18 | $256 |
| Biohaven Pharmaceuticals, Inc. | 7 | $229 |
| Medtronic | 9 | $223 |
| GSK | 13 | $210 |
| Esperion Therapeutics, Inc. | 15 | $208 |
| AstraZeneca(2 entities) | 8 | $202 |
| Vanda Pharmaceuticals Inc. | 9 | $200 |
| Merck | 6 | $114 |
| Axsome Therapeutics, Inc. | 1 | $106 |
| Corcept Therapeutics | 6 | $102 |
| Exact Sciences | 5 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $86 |
| Astellas Pharma US Inc | 4 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $74 |
| Lilly USA, LLC | 4 | $70 |
| Johnson & Johnson(2 entities) | 3 | $60 |
| Phathom Pharmaceuticals, Inc. | 2 | $59 |
| Sanofi-aventis U.S. LLC | 4 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Pear Therapeutics (US), Inc. | 1 | $48 |
| Corium, LLC | 2 | $38 |
| Bayer | 2 | $35 |
| Ardelyx, Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Convatec Inc. | 1 | $26 |
| Saluda Medical Americas, Inc. | 1 | $26 |
| Insulet Corporation | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| UCB, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Nevro Corp. | 1 | $15 |
| Novartis | 1 | $13 |
| Hologic Sales And Service, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$117
- Ozempic$111
- Auvelity$106
How this compares
$5,447 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $142,335 |
| RybelsusSemaglutide | 55 | $58,311 |
| EliquisApixaban | 47 | $51,179 |
| JanuviaSitagliptin Phosphate | 33 | $38,882 |
| MounjaroTirzepatide | 30 | $33,540 |
| Nurtec OdtRimegepant Sulfate | 22 | $25,713 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $21,089 |
| LinzessLinaclotide | 31 | $20,659 |
| FarxigaDapagliflozin Propanediol | 17 | $19,150 |
| VascepaIcosapent Ethyl | 27 | $13,646 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $13,282 |
| JardianceEmpagliflozin | 16 | $11,729 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $11,396 |
| DapagliflozinDapagliflozin Propanediol | 17 | $11,392 |
| NexletolBempedoic Acid | 11 | $8,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $277 | $200,646170 claims |
| PfizerEliquis, Nurtec Odt | $576 | $76,89269 claims |
| MerckJanuvia | $114 | $38,88233 claims |
| Lilly USA, LLCMounjaro | $70 | $33,54030 claims |
| AstraZenecaFarxiga, Symbicort | $202 | $32,43258 claims |
| AbbVieLinzess, Synthroid | $1,302 | $23,27385 claims |
| GSKTrelegy Ellipta | $210 | $21,08923 claims |
| Boehringer IngelheimJardiance | $256 | $11,72916 claims |
| Esperion Therapeutics, Inc.Nexletol | $208 | $8,49611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Louisville
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Rebecca BraunerLouisville$40K
- Thomas FreelsLouisville$20K
- Christy BakerLouisville$18K
- Blair WagnerLouisville$15K
- Kathryn WestLouisville$13K
- Kimberly RobinsonLouisville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.